Lakefront Biotherapeutics NV
LKFT
$27.05
-$0.44-1.60%
NASDAQ
| 03/31/2026 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -99.29% | 8.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.29% | 8.61% | |||
| Cost of Revenue | -67.35% | 3.51% | |||
| Gross Profit | -103.64% | 17.18% | |||
| SG&A Expenses | 8.40% | -18.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 96.68% | 32.19% | |||
| Total Operating Expenses | -36.02% | 0.17% | |||
| Operating Income | -107.92% | 12.64% | |||
| Income Before Tax | -98.24% | 153.43% | |||
| Income Tax Expenses | -89.64% | 78.62% | |||
| Earnings from Continuing Operations | -98.25% | 158.37% | |||
| Earnings from Discontinued Operations | 274.15% | -65.95% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.17% | -42.04% | |||
| EBIT | -107.92% | 12.64% | |||
| EBITDA | -106.83% | 0.20% | |||
| EPS Basic | -98.17% | -42.05% | |||
| Normalized Basic EPS | -98.35% | -- | |||
| EPS Diluted | -98.17% | -42.05% | |||
| Normalized Diluted EPS | -98.35% | -- | |||
| Average Basic Shares Outstanding | -0.05% | -0.05% | |||
| Average Diluted Shares Outstanding | -0.07% | -0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||